{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-112483","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2021-09-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.015584+00:00","generated_at":"2026-06-29T06:10:12.380003+00:00","sec_items":["5.02","7.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"medium","headline":"Rhythm Pharma CMO resigns; new CMO appointed; updated Phase 3 data on setmelanotide","bullets":["Dr. Murray Stewart resigns as CMO effective Sept 10, 2021; will serve as Senior Medical Advisor for up to one year at $12,000/month.","Linda Shapiro Manning, M.D., Ph.D., appointed as new CMO effective Sept 10; previously SVP Clinical.","Updated slide presentation includes new BMI reduction data from Phase 3 Bardet-Biedl syndrome trial and EMANATE powering assumptions.","Stewart's vested options remain exercisable 3 months post-consulting; unvested options forfeited; RSUs continue vesting.","Stewart eligible for prorated 2021 annual bonus based on employment and part-time consulting."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-112483","json":"https://secwatch.observer/filing/0001104659-21-112483.json","markdown":"https://secwatch.observer/filing/0001104659-21-112483.md","text":"https://secwatch.observer/filing/0001104659-21-112483.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000110465921112483/0001104659-21-112483-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000110465921112483/tm2126899d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T06:10:12.380003+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7189837d49","claim":"Linda Shapiro Manning was appointed as Chief Medical Officer at RHYTHM PHARMACEUTICALS, INC..","evidence_excerpt":"The Board has appointed Linda Shapiro Manning, M.D., Ph.D., currently Senior Vice President, Clinical of the Company, to succeed Dr. Stewart as Chief Medical Officer as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649904/000110465921112483/0001104659-21-112483-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"a479dbd6e7","claim":"Murray Stewart resigned as Chief Medical Officer at RHYTHM PHARMACEUTICALS, INC..","evidence_excerpt":"On August 31, 2021, Murray Stewart, D.M., F.R.C.P. notified Rhythm Pharmaceuticals, Inc. (the “Company”) of his resignation as Chief Medical Officer, effective as of September 10, 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649904/000110465921112483/0001104659-21-112483-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}